To Be Discontinued Topical Gel Dermatology
Podofilox Topical Gel · 226 days since initial FDA posting
Brand: CONDYLOX
FDA lists Podofilox Topical Gel as To Be Discontinued (AbbVie Inc.).
No availability text on this FDA row.
Podofilox Topical Gel: To Be Discontinued
FDA availability text is not recorded on this row. Contact your pharmacist if you are affected.
Shortage Details
- Generic Name
- Podofilox Topical Gel
- Manufacturer
- AbbVie Inc.
- Dosage Form
- Topical Gel
- Presentation
- Condylox , Topical Gel, 0.5% (NDC 0023-6118-03)
- Package NDC
- 0023-6118-03
Status & Timeline
- Status
- To Be Discontinued
- First Reported
- Jan 28, 2026
- Last Updated
- Jan 28, 2026
- Therapeutic Category
- Dermatology, Other
Row fields from the FDA Drug Shortages database via openFDA.
Shortage Reason
Discontinuation of the manufacture of the drug
FDA reason on file: Discontinuation of the manufacture of the drug. General shortage guidance lives on the tracker hub.